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ABSTRACT 
Objective: The objective of the present study was to develop and characterize an optimal stable nanosponges of Gliclazide (GLZ) by using the 
emulsion solvent diffusion method and aimed to increase its bioavailability and release the drug in sustained and controlled manner.  
Methods: The GLZ nanosponge was prepared by emulsion solvent diffusion method using different drug-polymer ratios (1:1 to 1:5) Eudragit S100 
is used as a polymer. Differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR) estimated the compatibility of 
GLZ with polymer. All formulations evaluated for production yield, entrapment efficiency, in vitro drug release, scanning electron microscopy (SEM) 
and stability studies. 
Results: The DSC and FTIR Studies revealed that no interaction between drug and polymer. The Production yield of all batches in the range of 
73.8±0.30 to 85.6±0.32. Batch F3 showed the highest production yield, the entrapment efficiency of batch F3 70.6±0.77. The average particle size 
ranges from 303±2.36 to 680±2.50 nm. By the end of 10th
Conclusion: The results of various evaluation parameters, revealed that GLZ nanosponges would be possible alternative delivery systems to 
conventional formulation to improve its bioavailability, the emulsion solvent diffusion method is best method for preparation of nanosponges and 
release the drug in sustained and controlled manner. 
 hour F3 formulation shown highest drug release was found to be 94.40±1.12%. The 
release kinetics of the optimized formulation shows zero-order drug release. The stability study indicates no significant change in the in vitro 
dissolution profile of optimized formulation. 
Keywords: Nanosponge, Gliclazide, Controlled release, Emulsion solvent diffusion method 




Nanosponge is a modern category of material and it is made up of 
tiny particles with a narrow cavity of few nanometers. These narrow 
cavities can be filled with various types of substances these tiny 
particles are having capability due to which it is able to carry both 
hydrophilic and lipophilic drug substances [1]. Release the drug at 
specific target site instead of circulate through the body it will more 
effective for particular given dosage [2, 3]. The invention of 
nanosponges has become significant step towards overcoming the 
complexity associated with the newly developing systems. The small 
size and porous nature of nanosponges can bind poorly water-
soluble drugs within the matrix and improve their solubility and 
bioavailability [4]. Nanosponges are able to entrap both hydrophilic 
as well as lipophilic drug molecules because of their inner 
hydrophobic cavities and external hydrophilic branching, thereby 
offering unparalleled flexibility. Nanosponge obtained by using 
suitable cross-linking agent also by different organic and inorganic 
materials [5]. The stability of these formulations over a wide range 
of pH in GI fluids and stable over 130 °C compatible with most 
vehicles and ingredients. Reducing dosing frequency and increase 
patient compliance and comfort. This drug delivery system having 
entrap wide variety of ingredients and reducing side effects, 
improve stability, increased elegance and formulation flexibility [6]. 
The effort to improve dissolution and solubility of poorly and 
practically water insoluble drugs remains one of the most 
challenging tasks in drug development. Several methods have been 
introduced to increase dissolution rate and thereby oral absorption 
and bioavailability of such drugs. Among various approaches, 
Nanosponges has shown promising results in improving solubility, 
wettability, dissolution rate of drug and subsequently its 
bioavailability [7]. The nanosponges can overcome some of the 
shortcomings of the conventional dosage forms. GLZ is one of the 
second-generation sulphonylurea, antidiabetic drug which 
stimulates insulin release. It is used for the treatment of non-insulin-
dependent diabetes mellitus. GLZ is classified under class II 
according to biopharmaceutical classification system (BCS). The 
drug shows low, pH dependent solubility. In acidic and neutral 
aqueous media, GLZ exhibits very poor solubility. This poor 
solubility may cause poor dissolution and unpredicted 
bioavailability. Preparation of nanosponges of GLZ to improve the 
dissolution rate of GLZ and subsequently its bioavailability. The 
main objective of the study was to increase the amount of dissolved 
drug molecules at the absorption site by increasing the dissolution 
rate, since for class II drugs like GLZ, in vivo dissolution rate is rate-
limiting step in drug absorption. nanosponges were selected as the 
method of choice since it would be easier in subsequent formulating. 
The nanosponges were prepared at various drug-to carrier weight 
ratios by emulsion solvent diffusion method. 
MATERIALS AND METHODS 
Materials 
Gliclazide (GLZ) was provided by Bal Pharma Bengaluru India. 
Eudragit S100 provided by Evonik Mumbai. Polyvinyl Alcohol (PVA), 
Dichloromethane (DCM), Triethyl citrate was obtained from 
chemdyes corporation Rajkot Gujrat India.  
Methods 
GLZ nanosponges were prepared by emulsion solvent diffusion 
method. In this method, two phases used are aqueous and organic. 
Aqueous phase consists of polyvinyl alcohol and organic phase 
include GLZ and Eudragit S100. After dissolving GLZ and Eudragit 
S100 to suitable organic solvent. This phase added slowly to the 
aqueous phase and stirred for two or more hours and then 
nanosponges are collected by filtration, washed, and then dried in 
air at room temperature or in vacuum oven 40 °C for 24 h [8]. 
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Table 1: Formulation of GLZ loaded nanosponges 
Materials  F1 F2 F3 F4 F5 
Drug: polymer(mg) 100:100 100:200 100:300 100:400 100:500 
PVA (%w/v) 0.5 0.5 0.5 0.5 0.5 
Dichloromethane (ml) 20 20 20 20 20 
Triethyl citrate (ml) 0.5 0.5 0.5 0.5 0.5 
Distilled water (ml) 100 100 100 100 100 
 
Preformulation studies of pure drug 
Construction of calibration curve  
Stock I. 
Accurately weighed 10 mg of GLZ was dissolved the insufficient 
amount of phosphate buffer 6.8 and volume was made to 10 ml with 
it. (conc 1000μg/ml) 
Stock II 
From stock-I 1 ml sample is withdrawn by pippete and diluted to 10 
ml of by using phosphate buffer 6.8(100μg/ml) 
Stock III 
From stock II Working standard solution of strengths 5, 10, 15, 20, 
25(μg/ml) were made from the stock solution by appropriate 
dilution. 
Drug-excipient compatibility studies  
The drug and excipient compatibility studies were carried out by 
Fourier transform-infrared spectroscopy (FT-IR). The Potassium 
Bromide pellets were prepared on KBr press on grounding the solid 
powder sample with 100 times the quantity of KBr in mortar. The 
spectra recorded over the wavenumber of 4000 to 400 cm-1
Evaluation studies of prepared nanosponges 
. 
From the results obtained by solubility and dissolution studies, 
nanosponges which showed better result was selected. For further 
characterization, nanosponges were performed to access 
interaction if any between the drug and polymer and also to find 
out what properties of polymer make them an effective material 
for solubility and bioavailability enhancement. In present study, 
the nanosponges of GLZ with Eudragit S100 were characterized by 
FT-IR, DSC, SEM, in vitro drug release study, production yield, 
entrapment efficiency etc. 
Production yield 
The production yield (PY) can be determined by calculating the 
initial weight of raw materials and final weight of nanosponges. 
Production yield =
Practical mass of nanosponges
Theoretical mass(polymer + drug)
× 100 
The percentage yield of different batches was determined by 
weighing the nanosponges after drying [9]. 
Drug entrapment efficiency  
To calculate the entrapment efficiency accurately weighed the 
quantity of nanosponges (10 mg) with 5 ml of methanol in a 
volumetric flask was shaken for 1 min using vortex mixer. The 
volume was made up to 10 ml. Then the solution was filtered and 
diluted and the concentration of GLZ was determined 
spectrophotometrically at 229 nm [9]. 
Loading efficiency =
Actual drug content in nanosponge
Theoretical drug content
× 100 
Determination of drug content 
To study the amount of drug incorporated in the nanosponges, GLZ 
was extracted from the nanosponges by dissolving them in 25 ml 
Methanol. The resulting solution was filtered through a 0.45-micron 
membrane filter. The GLZ content in the methanolic extracts was 
analyzed spectrophotometrically by using a UV-Visible 
spectrophotometer (UV Jasco V630) at a wavelength of 229 nm, 
against methanol as blank [10]. 
% drug content = (
Wa
Wt
) × 100 
Where,  
Wa = Actual drug content and  
Wt = Theoretical drug content 
Determination of particle size 
The size of particles is maintained during polymerization for the 
formation of free-following powders having fine aesthetic attributes. 
Particle size analysis of loaded and unloaded nanosponges 
performed by laser light diffractometry or Malvern zeta sizer. The 
cumulative graph is maintained or plotted as particle size against 
time to study effect of particle size on drug release [11]. 
In vitro drug release studies 
In vitro drug release studies were performed in triplicate using USP 
Paddle method at 50 rpm and 37±0.2 ˚C in 900 ml of phosphate buffer 
(pH 6.8) [12]. 100 mg of the formulated nanosponges is used for each 
experiment. Samples were taken at appropriate time intervals for 1 h 
interval for 10hr. The samples were measured spectrophotometrically 
at 229 nm. Fresh dissolution medium was replenished each time when 
sample is withdrawn to compensate the volume. 
Fourier-transform infrared analysis 
Fourier-transform infrared (FTIR) spectra of pure GLZ and pure 
polymer (Eudragit), and nanosponges of drug GLZ was taken to 
access interaction if any interaction between drug and polymer in 
mixtures. The scanned mixture by using an FTIR (Jasco-460 plus). 
The FTIR spectra of mixtures were compared with that of the pure 
drug and Polymer to assess any change in the principle peaks of 
spectra of pure drug and polymer [13]. 
Differential scanning calorimetry 
Differential scanning calorimetric (DSC) studies of pure GLZ, pure 
polymer (Eudragit S100) and nanosponges of drug GLZ with Eudragit 
S100 was performed to assess what changes happen during the heat 
change and thermal behavior of the drug is also determine. The pure 
drug sample shows sharp endothermic peak at melting point of drug. 
The samples were kept on DSC reference pan and DSC curves were 
obtained by differential scanning calorimeter (DSC 60; Shimadzu) at a 
heating rate of 10 °C/min from 0 to 300 °C in nitrogen atmosphere [14]. 
Scanning electron microscopy studies 
Scanning electron microscopy (JSM-5200, Tokyo Japan) was used to 
analyze particle size and surface topography was operated at 15kV 
acceleration voltage. A concentrated aqueous suspension was spread 
over a slab and dried under vacuum. The sample was shadowed in a 
cathodic evaporator with a gold layer 20 nm thick. Photographs 
were elaborated by an image processing program and individual NP 
diameters were measured to obtain mean particle size. 
Nanosponges that showed the best results in the solubility and 
dissolution studies were subjected to scanning electron microscopy 
(SEM) studies to confirm the changes mounting made during the 
formation of nanosponges. Samples were prepared by powder onto a 
brass stub using graphite glue and coated with gold under vacuum 
before use. Images were recorded at the required magnification at an 
acceleration voltage of 10 KV using a scanning electron microscope [15]. 
Borge et al. 




Accelerated stability studies: -40 °C±2 °C/75%RH±5%RH. As per 
ICH guidelines, the samples for stability analysis must be exposed 
to an environment of 40̊C ±2˚C/75%RH±5 % RH for a period of 6 
mo. As per the standard protocol, the samples must be analysed at 
0, 1, 2, 3-and 6-months’ time points. Accelerated stability studies 
were performed for the final optimized formulation. Samples were 








Calibration curve of GLZ 
Evaluation of nanosonges 
Production yield 
The production yield (PY) can be determined by calculating the 
initial weight of raw materials and final weight of nanosponges. 
The percentage yield of different batches was determined by 
weighing the nanosponges after drying. The percentage yields of 
different formulations were found to be in the range of 73.8±0.30%-
85.6±0.32% as shown in below table 2. 
Drug entrapment efficiency 
The drug entrapment efficiency found in the range of 62.8±0.22 to 
73.1±0.39. The increases concentration of polymer the drug 
entrapment efficiency also increases. 
 
Table 2: Percentage yield of different batches of nanosponges 
S. No. Batch Yield (%) 
1 F1 73.8±0.30 
2 F2 75.2±0.25 
3 F3 85.6±0.32 
4 F4 78.9±0.18 
5 F5 80.1±0.16 
 Average of three values±SD n=3 
 
Table 3: Drug entrapment efficiency of different batches of nanosponges 
S. No. Batch Entrapment efficiency (%) 
1 F1 62.8±0.22 
2 F2 66.2.±0.25 
3 F3 70.6±0.77 
4 F4 71.8±0.36 
5 F5 73.1±0.39 
Average of three values±SD n=3 
 
Determination of drug content  
The various batches of the nanosponges were subjected for drug 
content analysis. The powdered nanosponges (30 mg) were 
dissolved in adequate quantity (100 ml) of phosphate buffer PH 6.8 
then filter. The UV absorbance of the filtrate was measured using a 
UV spectrophotometer at 229 nm.  
The drug content of different formulation was found to be in the 
range of 77.21±0.17 to 90.62±0.25 as shown in below table 4. 
 
Table 4: Drug content values of different batches of nanosponges 
S. No. Batch Drug content (%) 
1 F1 77.21±0.17 
2 F2 83.36±0.11 
3 F3 90.62±0.25 
4 F4 85.32±0.13 
5 F5 86.92±0.09 
Average of three values±SD n=3 
Borge et al. 
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Particle size analysis 
The average particle size was obtained in range of 303±2.36 nm to 
680±2.50 nm. The change in the concentration of polymer results in 
variation of particle size of nanosponges.  
The average particle size of formulation batch F3 showed minimum 
particle size i.e. 418±2.23 nm while formulation batch F5 showed 
maximum particle size i.e. 680±2.50 nm. An increase in the 
concentration of polymer leads to increase in the particle size of 
nanosponges. 
 
Table 5: Particle size of different batches of nanosponges 
S. No. Formulation code Particle size (nm) 
1 F1 303±2.36 
2 F2 380±2.59 
3 F3 418±2.23 
4 F4 519±2.66 
5 F5 680±2.50 
Average of three values±SD n=3 
 
In vitro drug release study  
In vitro drug release for GLZ loaded nanosponges for a period of 10 
h, was carried out by using Phosphate buffer (pH 6.8) at 37±50◦ C 
using cellophane membrane of 0.22 nm. From the dissolution profile 
of formulations F1 to F5, it is concluded that formulation batch F3 
shows a better drug release profile than other formulations. 
Cumulative % release has been shown for average of three 
preparations, Cumulative % drug release for all the formulations are 
depicted in the table 6. 
 
Table 6: In vitro drug release studies 
Time in (h) % Drug release of nanosponges 
1:1 1:2 1:3 1:4 1:5 
1 10.07±0.90 11.99±1.12 15.25±0.78 13.36±1.42 10.04±0.92 
2 15.32±0.85 23.58±0.80 19.48±0.82 20.22±1.36 20.53±1.00 
3 25.36±0.92 32.72±0.99 33.79±1.02 31.98±0.96 31.76±1.14 
4 39.98±0.65 40.347±1.2 51.93±0.98 42.46±1.22 40.29±1.50 
5 49.92±1.12 50.38±1.50 65.03±1.14 56.34±1.33 44.42±1.04 
6 55.23±1.01 58.3±0.98 69.3±1.32 65.72±1.18 50.97±1.22 
7 63.74±0.58 64.71±1.11 77.74±1.26 71.12±1.08 61.36±1.16 
8 70.98±1.20 75.98±0.96 82.15±1.08 77.92±1.12 76.32±1.32 
9 75.26±0.74 81.52±1.25 85.78±0.98 86.24±0.90 84.28±1.24 
10 84.32±0.62 87.36±1.32 94.40±1.12 91.40±0.88 90.32±1.20 
Average of three values±SD n=3 
 
 
Fig. 2: Graphical presentation of % drug release of F1 to F5 batches 
 
Modeling of dissolution profile 
In the present study, different release kinetic equations (zero order, 
first order, Higuchi equation and Korsmeyer-peppas equation) were 
applied to interpret the release rate of drug from nanosponges. The 
data of in vitro release were fitted to these models and equations to 
explain the release kinetics of GLZ from nanosponges [17]. 
Borge et al. 




Fig. 3: Zero order release kinetics 
 
 
Fig. 4: First order release kinetics 
 
 
Fig. 5: Higuchi model 
 
 
Fig. 6: Korsmeyer-peppas model 
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values of different release kinetic models 
Zero order kinetics First order kinetics Higuchi model Korsmeyer-Peppas model 
R R2 R2 R2 2 
F1 0.9823 0.9529 0.9326 0.8079 
F2 0.9612 0.9462 0.9524 0.7541 
F3 0.9927 0.9711 0.9475 0.7425 
F4 0.9865 0.9576 0.9462 0.7608 
F5 0.9923 0.9021 0.9205 0.7878 
 
The in vitro release profile of the formulations indicates that the rate 
of drug release was higher for formulations, among all the 
formulations F3 shows more amount of drug release with the 
medium amount of polymer ratio. The plot of time vs cumulative % 
drug release in the zero-order kinetic model the regression 
coefficient value shows linearity as shown in (fig 3). The slopes and 
regression coefficient values (R2
 
) of various mathematical models 
for optimized batch F3, 0.9927, 0.9711, 0.9475, 0.7425 for zero 
order, first order, Higuchi and Peppas model respectively. The good 
linearity observed with the zero-order and regression coefficient 




Fig. 7: FT-IR spectra of pure GLZ 
 
 
Fig. 8: FT-IR spectra of Eudragit S100 
 
 
Fig. 9: FT-IR spectra of the physical mixture (drug+polymer) 
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Fig. 11: DSC thermogram of Pure GLZ 
 
 
Fig. 12: DSC thermogram of polymer 
 
 
Fig. 13: DSC thermogram of the physical mixture (drug+polymer) 
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Fig. 15: SEM image of nanosponges 
 
Stability studies 
Optimized formulation was subjected to stability studies as per ICH 
guidelines. Various parameters such as drug content, and in vitro 
drug release were measured before and after 30, 60, days of 
stability. Results of stability studies are shown in below table 8. 
Results of stability studies showed there is no significant change in 
the above mentioned parameter after elevated temperature and 
humidity conditions during stability studies. Thus, it can be proved 
from the stability studies that the prepared formulation is stable and 
not much affected by elevated humidity and temperature conditions 
Stability studies. 
 
Table 8: Stability study of optimized formulation 
Time (day) Drug content (%) In vitro drug release (%) 
0 98.86±0.68 99.85% 
30 98.20±0.99 99.74% 
60 98.30±1.50 99.51% 
 
DISCUSSION 
The calibration curve of GLZ by UV method showed the linearity in 
absorbance and coefficient of regression found to be 0.9994. The IR 
studies shows that there is no interaction found between drug and 
excipients. All the characteristic peaks of GLZ were present in the 
spectrum of drug (fig. 7) and prepared GLZ nanosponges (fig. 10), 
indicating compatibility in drug and polymer the spectrum 
confirmed that there is no significant change in the chemical 
integrity of the drug [18]. The DSC thermogram pure GLZ shows 
sharp endothermic peak at 174̊C , which is its melting point as it 
melts with decomposition [19]. Such a sharp endothermic peak 
indicates that GLZ used was in the pure crystalline state. The 
thermogram of prepared GLZ nanosponges 1:3 (fig. 14) displayed 
the nanosponge structure is amorphous as no sharp melting peak is 
shown.  
Borge et al. 
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The percentage yield of different batches was determined by 
weighing the nanosponges after drying. The percentage yields of 
different formulations were found to be in the range of 73.8±0.30%-
85.6±0.32%. The drug entrapment efficiency found in the range of 
62.8±0.22 to 73.1±0.39. The increases concentration of polymer the 
drug entrapment efficiency also increases. The drug content of 
different formulation was found to be in range of 77.21±0.17 to 
90.62±0.25. The average Particle size was obtained in range of 
303±2.36 nm to 680±2.50 nm. The Change in the concentration of 
polymer results variation in particle size of nanosponges [20]. The 
average particle size of formulation batch F1 showed minimum 
particle size i.e. 303±2.36 nm while formulation batch F5 showed 
maximum particle size i.e. 680±2.50 nm. An increase in the 
concentration of polymer leads to increase in the particle size of 
nanosponges. The SEM of the prepared nanosponges revealed a 
porous nature of GLZ nanosponges (fig. 15). Drug release data for 
the nanosponge formulation fitted into various release kinetic 
equations to find out order of drug release. The various release 
kinetic curves are shown in fig. 3-7. The correlation coefficient 
showed that the release profile followed the zero-order drug release 
(R2
CONCLUSION 
=0.9927) from these results it is apparent that the regression 
coefficient value closer to unity in case of zero order kinetic model. 
The data indicate more linearity when plotted by the zero-order 
kinetic model. Hence, it can be concluded that the major mechanism 
of drug release follows zero-order kinetics [21]. 
Nanosponge is the best novel drug delivery system. For improving 
the dissolution and bioavailability profile of poorly water-soluble 
drug. BCS class-2 drug are more suitable drug candidate for 
formulated into nanosponges. Nanosponges are able to encapsulate 
variety of various types of drug molecules. Nanosponges prepared 
by using emulsion solvent diffusion method are simpler and 
production cost of method is less. Nanosponge prepared by 
emulsion solvent diffusion method shows good entrapment 
efficiency ranged between 62.8±0.22 to 73.1±0.39 and optimum 
drug release is 94.40%. The compatibility of drug and polymer 
determine by FT-IR, and DSC study. The result of IR and DSC shows 
drug and polymer are compatible to each other. The nanosponge 
formulation shows zero order drug release. The outcome of the 
study concluded that Eudragit S100 are employed as polymer for 
oral drug delivery system. Nanosponges of gliclazide increases 
solubility and dissolution rate of drug. The emulsion solvent 
diffusion method is best method for preparation of nanosponges. 
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